Cancer Communications (Sep 2023)
A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations
- Pingli Wang,
- Liming Cao,
- Panwen Tian,
- Shengxiang Ren,
- Liyun Miao,
- Chengzhi Zhou,
- Yun Fan,
- Yuping Li,
- Dongqing Lv,
- Xin Zhao,
- Mei Yang,
- Chaonan Zhu,
- Bing Yu,
- June Xu,
- Yong Song,
- Kai Wang
Affiliations
- Pingli Wang
- Department of Respiratory and Critical Care Medicine The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China
- Liming Cao
- Department of Respiratory Medicine Xiangya Hospital Central South University Changsha Hunan P. R. China
- Panwen Tian
- Department of Respiratory and Critical Care Medicine West China Hospital of Sichuan University Chengdu Sichuan P. R. China
- Shengxiang Ren
- Department of Medical Oncology Shanghai Pulmonary Hospital Shanghai P. R. China
- Liyun Miao
- Department of Respiratory Medicine The Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu P. R. China
- Chengzhi Zhou
- Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong P. R. China
- Yun Fan
- Department of Medical Thoracic Oncology Cancer Hospital of University of Chinese Academy of Sciences Hangzhou Zhejiang P. R. China
- Yuping Li
- Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang P. R. China
- Dongqing Lv
- Department of Respiratory Medicine Taizhou Hospital of Zhejiang Province Taizhou Zhejiang P. R. China
- Xin Zhao
- Department of Respiratory and Critical Care Medicine Jiangsu Province Hospital The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu P. R. China
- Mei Yang
- Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China
- Chaonan Zhu
- Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China
- Bing Yu
- Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China
- June Xu
- Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China
- Yong Song
- Department of Respiratory Medicine General Hospital of Eastern Theater Command Nanjing Jiangsu P. R. China
- Kai Wang
- Department of Respiratory and Critical Care Medicine The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China
- DOI
- https://doi.org/10.1002/cac2.12456
- Journal volume & issue
-
Vol. 43,
no. 9
pp. 1059 – 1063
Abstract
No abstracts available.
